Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer

Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT07251582 by Hunan Province Tumor Hospital, with a registry enrolment figure of 186 participants, started 2026-08-12 and due to reach its primary completion in 2028-10-31. Interventions recorded: Time of Day-based Assignment for Infusion of Immune Checkpoint Inhibitor (e.g., toripalimab, or pembrolizumab) + platinum-based chemotherapy. Conditions listed: Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC). Primary outcome: Pathological Complete Response (pCR) rate. Lung eligibility wording from the registry: "Histologically or cytologically confirmed diagnosis of resectable stage II to III non-small cell lung cancer (NSCLC)". Sites: China. No results are recorded here; the registry entry is the source.